Abstract
The new cystic fibrosis drug Kalydeco illustrates both the promise and peril of personalized medicine: It is extremely expensive and helps only 4% of people with the disease, or 1200 patients.
Publisher
American Association for the Advancement of Science (AAAS)
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献